Male doctor talking to a female patient.
Oncology | Blood Cancer

Detecting CALR mutations should always be this easy

Empower oncologist-hematologists with the confidence they need

CALR gene mutations in MPNs

A significant number of patients with o myelaproliferotive neoplasm (MPN) hove a mutation in the CALR gene. A CALR mutation is found in 20%-25% o f essential thrombocythem ia (ET) and primary myelofibrosis (PMF) cases.*

The presence o f CALR mutations is a major diagnostic criterion for MPNs in WHO 2016 guidelines.**

Detecting relevant biomarkers like CALR enables oncologist-hematologists and researchers to help advance MPN research.

Female scientist working in a laboratory

Reliably detect CALR mutations 

Our CALR solutions let you analyze CALR mutations with the same workflow you use for JAK2 V617F testing.

With the CALR mutation testing kits, you can be sure of :

  • Reliable qualitative detection of CALR exon 9 mutations (c.1091_1162 region) and identification of Types 1 & 2 in the same real-time PCR run
  • Multiple results with just one instrument and one real-time PCR step
  • An Integrated, ready-to-use workflow that saves time and lowers costs.
  • Increased lab efficiency

CALR mutation clinical research

Since their discovery in MPNs in 2013, CALR mutations have remained highly relevant to advancing MPN clinical research.***

Where MPN research applications require a straightforward detection of CALR mutations with specific identification of types 1 & 2, our CALR RGQ PCR Kit will deliver.

Browse our region-specific CALR tests

References:

* Wu Z, Zhong C, Mo X, Guan M. Clinical relevance between CALR mutation and myeloproliferotive neoplasms. Stem Cell lnvestig. 2015 Feb 16;2:4. do;: 10.3978/p,sn.2306-9759.2015.0l.03. PMID: 27358872; PMCID: PMC4923639.

**The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia (2016}. https:// ash publicalions.org/blood/ article/ 127 /20/2391/35255/The-2016-revision-lo-the-World-Health-Organizalion (accessed May l 0, 2022)

*** Joan How, Gabriela S. Hobbs, Ann Mullally; M ulantcalreliculin in myeloproliferalive neoplasms. Blood 2019; 134 (25): 2242 - 2248. doi: http,://doLo,g/lO. l l 82/blood.2019000622.